Consider ENBREL for Patients with Psoriatic Arthritis
Psoriatic arthritis (PsA) is an inflammatory autoimmune disorder that affects the skin and both proximal and distal joints.1
ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
In the PsA pivotal study, patients on ENBREL achieved significant clinical efficacy in PsA2:
signs and symptoms
See change from baseline in pain, morning stiffness, and CRP.
See reductions in HAQ score out to Year 2.
Inhibited progression of
See changes in mTSS out to Year 2.
See improvements in mean PASI score.
PsA can cause substantial impairment of physical function and may lead to progressive joint damage
Impairment of physical function1,3:
- Physical function generally worsens as the number of inflamed joints and disease activity increase
Joint damage occurs progressively1,3,4:
- Joint damage may progress despite improvements in symptoms3,4
- The percentage of patients with joint erosions increased from 27% to 47% over 2 years in one study1
In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.